How can we improve peptide drug discovery? Learning from the past
- 4 August 2021
- journal article
- editorial
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 16 (12) , 1399-1402
Abstract
With more than 80 peptides now FDA approved and hundreds more in preclinical or clinical trials there is no doubt that peptides are having an impact in the pharmaceutical industry [1–4]. That this ...Keywords
Funding Information
- laboratory on peptides is funded by a grant from the Australian Research Council (CE200100012)
This publication has 34 references indexed in Scilit:
- Ribosomally synthesized and post-translationally modified peptide natural product discovery in the genomic eraCurrent Opinion in Chemical Biology, 2017
- Cyclic peptide therapeutics: past, present and futureCurrent Opinion in Chemical Biology, 2017
- Accurate de novo design of hyperstable constrained peptidesNature, 2016
- A Synthetic Factor XIIa Inhibitor Blocks Selectively Intrinsic Coagulation InitiationACS Chemical Biology, 2015
- Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficientsProceedings of the National Academy of Sciences, 2014
- Multifaceted Roles of Disulfide Bonds. Peptides as TherapeuticsChemical Reviews, 2013
- Design of a Cyclotide Antagonist of Neuropilin-1 and -2 That Potently Inhibits Endothelial Cell MigrationACS Chemical Biology, 2013
- The Future of Peptide‐based DrugsChemical Biology & Drug Design, 2012
- Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1Expert Opinion on Drug Discovery, 2012
- Manufacturing Peptides as Active Pharmaceutical IngredientsFuture Medicinal Chemistry, 2009